ImmuCell

ICCC

Market cap $56.2M

ICCC's innovative, antibiotic-free cattle health products drive margin recovery, real-world adoption and stock gains.

ImmuCell tumbles despite stronger margins and a rebound in EPS, as backlog dynamics pressure quarterly sales while management highlights improving operations.

ImmuCell Corporation ( ICCC ) Q3 2025 Earnings Call November 14, 2025 9:00 AM EST Company Participants Michael Brigham - Special Advisor to the CEO & Director P. F. Te Boekhorst - President, CEO & Director Timothy Fiori - CFO, Secretary, Treasurer & Director Conference Call Participants Joe Diaz - Lytham Partners, LLC Frank Gasca George Melas - MKH Management Company, LLC Presentation Operator Good morning, and welcome to the ImmuCell Corporation Reports Third Quarter ended September 30, 2025, Unaudited Financial Results Conference Call.

PORTLAND, Maine, Nov. 13, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended September 30, 2025.

PORTLAND, Maine, Nov. 06, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended September 30, 2025 after the market closes on Thursday, November 13, 2025. The Company is planning to host a conference call the next morning, Friday, November 14, 2025, at 9:00 AM ET to review the unaudited financial results.

PORTLAND, Maine, Nov. 04, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced the start date of its new CEO and related board changes.

PORTLAND, Maine, Oct. 07, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the third quarter of 2025.

PORTLAND, Maine, Sept. 29, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that it has selected Olivier te Boekhorst as its next President and CEO. The Company anticipates a start date of November 1, 2025 for Mr. te Boekhorst.

ICCC posts Q2 profit on higher sales and margins, but shares fall as investors weigh one-time boosts and Re-Tain's delayed commercialization.

ImmuCell Corporation (NASDAQ:ICCC ) Q2 2025 Earnings Conference Call August 15, 2025 9:00 AM ET Company Participants Michael F. Brigham - President, CEO, Treasurer, Secretary & Director Timothy C.